The breath print represents a novel biomarker of malnutrition in pulmonary arterial hypertension: a proof‐of‐concept study

2021 ◽  
Author(s):  
Jacob T. Mey ◽  
Mary C. Rath ◽  
Kathleen McLaughlin ◽  
Marianne Galang ◽  
Kathryn Lynch ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Proof Of Concept ◽  
Concept Study ◽  
Pulmonary Arterial

scholarly journals A prescribed walking regimen plus arginine supplementation improves function and quality of life for patients with pulmonary arterial hypertension: a pilot study

2017 ◽  
Vol 8 (1) ◽  
pp. 204589321774396 ◽  
Author(s):  
Mary Beth Brown ◽  
Attie Kempf ◽  
Catherine M. Collins ◽  
Gary M. Long ◽  
Matthew Owens ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Current Evidence ◽  
Proof Of Concept ◽  
Concept Study ◽  
Sf 36 ◽  
Pulmonary Arterial ◽  
Arginine Supplementation

Current evidence suggests that exercise training is beneficial in pulmonary arterial hypertension (PAH). Unfortunately, the standard supervised, hospital-based programs limit patient accessibility to this important intervention. Our proof-of-concept study aimed to provide insight into the usefulness of a prescribed walking regimen along with arginine supplementation to improve outcomes for patients with PAH. Twelve PAH patients (all women) in New York Heart Association (NYHA) functional class (FC) II (n = 7) or III (n = 5) and in stable condition for ≥ 3 months were enrolled. Patients performed home- and fitness-center- based walking at 65–75% heart rate (HR) reserve for 45 min, six sessions/week for 12 weeks. Concomitant L-arginine supplementation (6000 mg/day) was provided to maximize beneficial endothelial training adaptations. Cardiopulmonary exercise testing, 6-min walk testing (6MWT), echocardiography, laboratory studies, and quality of life (QoL) survey (SF-36) were performed at baseline and 12 weeks. Eleven patients completed the study (72 session adherence rate = 96 ± 3%). Objective improvement was demonstrated by the 6MWT distance (increased by 40 ± 13 m, P = 0.01), VO2max (increased by 2 ± 0.7 mL/kg/min, P = 0.02), time-to-VO2max (increased by 2.5 ± 0.6 min, P = 0.001), VO2 at anaerobic threshold (increased by 1.3 ± 0.5 mL/kg/min, P = 0.04), HR recovery (reduced by 68 ± 23% in slope, P = 0.01), and SF-36 subscales of Physical Functioning and Energy/Fatigue (increased by 70 ± 34% and 74 ± 34%, respectively, P < 0.05). No adverse events occurred, and right ventricular function and brain natriuretic peptide levels remained stable, suggesting safety of the intervention. This proof-of-concept study indicates that a simple walking regimen with arginine supplementation is a safe and efficacious intervention for clinically stable PAH patients, with gains in objective function and QoL measures. Further investigation in a randomized controlled trial is warranted.

scholarly journals Estrogen metabolites in a small cohort of patients with idiopathic pulmonary arterial hypertension

2020 ◽  
Vol 10 (1) ◽  
pp. 204589402090878
Author(s):  
Nina Denver ◽  
Natalie Z.M. Homer ◽  
Ruth Andrew ◽  
Katie Y. Harvey ◽  
Nicholas Morrell ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Pulmonary Arteries ◽  
Metabolite Profile ◽  
Idiopathic Pulmonary Arterial Hypertension ◽  
Proof Of Concept ◽  
Increased Risk ◽  
Small Cohort ◽  
Pulmonary Arterial ◽  
Estradiol Metabolism

Increased risk and severity of idiopathic pulmonary arterial hypertension (iPAH) is associated with elevated estradiol in men and postmenopausal women. Pulmonary arteries synthesise estradiol via aromatase and metabolise it via CYP1B1 to mitogenic metabolites; SNPs in aromatase and CYP1B1 have been associated with PAH. This suggests that estradiol metabolism could be altered in iPAH. This proof-of-concept study profiles estradiol and several metabolites of estradiol simultaneously in serum from iPAH patients and controls. We show that the estradiol and metabolite profile is altered in iPAH and that 16-hydroxyestrone and 16-hydroxyestradiol accumulate in iPAH patients with 16-hydroxyestrone levels relating to disease severity.

scholarly journals Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial

2019 ◽  
Vol 176 (9) ◽  
pp. 1251-1267 ◽  
Author(s):  
Adrian J. Hobbs ◽  
Amie J. Moyes ◽  
Reshma S. Baliga ◽  
Dipa Ghedia ◽  
Rachel Ochiel ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Proof Of Concept ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Pulmonary Arterial ◽  
Neprilysin Inhibition

A Proof of Concept for the Detection and Classification of Pulmonary Arterial Hypertension through Breath Analysis with a Sensor Array

2013 ◽  
Vol 188 (6) ◽  
pp. 756-759 ◽  
Author(s):  
Sylvia Cohen-Kaminsky ◽  
Morad Nakhleh ◽  
Frédéric Perros ◽  
David Montani ◽  
Barbara Girerd ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Sensor Array ◽  
Breath Analysis ◽  
Proof Of Concept ◽  
Pulmonary Arterial
Sign in / Sign up

Export Citation Format

Share Document